GENETIC TECHNOLOGIES LTD
DelistedCIK 1166272fmd_1TB1ZH4AQZXX3P6EF2T4YFV3T9Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jul 01, 2015 to Jun 30, 2024, 16 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | 0 | 0 | 7 | 9 | 8 |
| Cost of revenue | 1 | 0 | 0 | 0 | 0 | 0 | – | – | – |
| Gross profit | 0 | 0 | (0) | (0) | (0) | (0) | – | – | – |
| Research and development | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 |
| Selling, general and administrative | 7 | 6 | 4 | 4 | 5 | 5 | – | – | – |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income before taxes | (8) | (8) | (5) | (6) | (6) | (7) | (7) | (12) | (12) |
| Income tax expense | – | – | – | – | – | – | (0) | (0) | – |
| Net income from continuing operations | – | – | – | – | – | – | (7) | (12) | – |
| Net income | (8) | (8) | (5) | (6) | (6) | (7) | (7) | (12) | (12) |
| Net income to common shareholders | (8) | (8) | (5) | (6) | (6) | (7) | – | – | – |